Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma

BACKGROUND: Combination immunotherapy is now considered the standard first-line therapy for patients with metastatic clear cell renal cell carcinoma (mccRCC) after multiple clinical trials demonstrated improved overall survival compared with single-agent tyrosine kinase inhibitors. Cabozantinib modu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haoran, Sahu, Kamal Kant, Brundage, James, Benson, Mallory, Swami, Umang, Boucher, Kenneth M, Gupta, Sumati, Hawks, Josiah, Sirohi, Deepika, Agarwal, Neeraj, Maughan, Benjamin L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400129/
https://www.ncbi.nlm.nih.gov/pubmed/36952231
http://dx.doi.org/10.1093/oncolo/oyad019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400129/
https://www.ncbi.nlm.nih.gov/pubmed/36952231
http://dx.doi.org/10.1093/oncolo/oyad019

Ejemplares similares